title: The effect of prostaglandin analogs and prostamide on central corneal thickness.
abstract: OBJECTIVE
  The aim of this study was to verify the influence of prostaglandin analogs and prostamide on central corneal thickness (CCT).
  
  
  METHODS
  A prospective analysis was done of CCT in glautomatous patients submitted to monotherapy with prostaglandin analogs (latanoprost 0.005% or travoprost 0.004%) or prostamide (bimatoprost 0.03%) during an 8-week period. A control group of patients without any ocular medication was also evaluated. CCT measurements were performed with a commercially available ultrasound pachymeter. A total of 73 patients were included in this study. Mean age was 68.5 +/- 9.2 (range, 48-85) years old.
  
  
  RESULTS
  A statistically significant reduction in CCT was observed in all groups, except the control group (n = 21): Bimatoprost 0.03% group (n = 21): 544.41 +/- 35.4 vs. 540.35 +/- 35.9 microm (P = 0.039); travoprost 0.004% group (n = 17): 538.47 +/- 32.0 vs. 532.25 +/- 30.4 microm (P = 0.009); latanoprost 0.005% group (n = 14): 548.57 +/- 32.4 vs. 543.88 +/- 35.6 microm (P = 0.036).
  
  
  CONCLUSIONS
  Topical therapy with prostaglandin analogs and bimatoprost is associated with CCT reduction over a period of at least 8 weeks.
authors.affiliation: Department of Opthalmology, University of São Paulo School of Medicine, São Paulo, Brazil. info@centroavancado.net
authors.forename: Marcelo
authors.initials: M
authors.lastname: Hatanaka
authors.forename: Roberto M
authors.initials: RM
authors.lastname: Vessani
authors.forename: Isalina R
authors.initials: IR
authors.lastname: Elias
authors.forename: Celso
authors.initials: C
authors.lastname: Morita
authors.forename: Remo
authors.initials: R
authors.lastname: Susanna
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D003315:Cornea / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D003941:Diagnostic Techniques, Ophthalmological; D005260:Female; D005902:Glaucoma, Open-Angle / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology / Q000627:therapeutic use; D011465:Prostaglandins, Synthetic / Q000494:pharmacology* / Q000627:therapeutic use; D000069557:Travoprost; D014463:Ultrasonography
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost